Twenty-one patients (15 men, 6 women, median age 67) were given a diagnosis of malignant pleural mesothelioma between March 1998 and December 2007 in our hospital. There was apparent occupational exposure of asbestos in 11 patients and suspicion of asbestos exposure in 5. Mean period recuired for diagnosis was 60 days with VATS and percutaneous needle biopsy. Eight patients underwent pleuropneumonectomy. Their median survival was 14.4 months, and the 2-year survival rate was approximately 30%. Seven other patients received chemotherapy, another patient underwent palliative radiotherapy and the remaining 5 patients received best supportive care. One patient had long survived (41.6 months) with gemcitabine-based chemotherapy. In the Senshu district, in the southern part of Osaka, there have been many asbestos spinning mills, so environmental exposure might occur. We should try to diagnose malignant mesothelioma for patients with pleural effusion even if they apparently do not have a history of asbestos exposure.
Download full-text PDF |
Source |
---|
Cancer Control
January 2025
Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Background: The proportion and impact of minimal pleural effusion (PE) on prognosis remain blurred in operable non-small cell lung cancer (NSCLC) patients who reported minimal PE on imaging.
Methods: Clinical and prognostic data of operable NSCLC patients who presented no distant metastasis, no direct pleural invasion, but minimal PE on preoperative imaging were retrospectively analyzed. The patients were divided into surgical (81 cases) and non-surgical (10 cases) cohorts.
Radiol Case Rep
March 2025
Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, 601 N Caroline St, Baltimore, MD, 21287, USA.
Solitary fibrous tumors are rare and typically benign fibroblastic neoplasms with a mean age of onset ranging from 60 to 70 years. Solitary fibrous tumors may arise anywhere within the body, however the pleura is the most common site of origin for these tumors, with approximately 30% of tumors arising from the pleura. In this report we highlight the case of a 62-year-old woman who presented with gradually progressive left sided chest pain that was eventually diagnosed as a pleural SFT.
View Article and Find Full Text PDFJ Cardiothorac Surg
January 2025
Department of Thoracic Surgery, Ningbo No.2 Hospital, 41 Xibei Road, Ningbo, 315010, P. R. China.
Pulmonary hamartomas are common. However, extrapulmonary hamartomas on the Visceral Pleura are very rare. We treated a patient with a pulmonary nodule at the left lower lobe by uniportal video-assisted thoracoscopic wedge resection, which showed a yellow nodule located on the visceral pleura.
View Article and Find Full Text PDFBMC Med
January 2025
Department of Radiology, Medical University of South Carolina, 171 Ashley Ave, Charleston, SC, 29425, USA.
Background: Lung cancer is a leading cause of cancer-related mortality. Non-small cell lung cancer (NSCLC) comprises 85% of cases with rising incidence among never-smokers (NS). This study seeks to compare clinical, imaging, pathology, and outcomes between NS and ever-smokers (S) NSCLC patients to identify significant differences if any.
View Article and Find Full Text PDFCancer Res Treat
December 2024
Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Purpose: This study aimed to evaluate the clinical impact of main tumor resection on long-term survival compared with pleural biopsy alone in patients with lung adenocarcinoma who were intraoperatively diagnosed with pleural metastasis.
Materials And Methods: A total of 176 patients with adenocarcinoma who had unexpected pleural metastasis detected during surgery from 2002 to 2021 were retrospectively analyzed. Each surgeon decided whether to perform main tumor resection or pleural biopsy alone.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!